Dysregulated modifications of Tau and/or mutations of MAPT underlie the pathogenesis of Tauopathy that includes Alzheimer’s disease, frontotemporal dementia, Pick’s disease, etc., making Tau a promising target for Tauopathy treatment [4–6]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.